ME02852B - Upotreba sigma liganada kod bola usled raka kostiju - Google Patents
Upotreba sigma liganada kod bola usled raka kostijuInfo
- Publication number
- ME02852B ME02852B MEP-2017-120A MEP12017A ME02852B ME 02852 B ME02852 B ME 02852B ME P12017 A MEP12017 A ME P12017A ME 02852 B ME02852 B ME 02852B
- Authority
- ME
- Montenegro
- Prior art keywords
- sigma ligand
- bone cancer
- pain
- opioid
- use according
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4152—1,2-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/18—One oxygen or sulfur atom
- C07D231/20—One oxygen atom attached in position 3 or 5
- C07D231/22—One oxygen atom attached in position 3 or 5 with aryl radicals attached to ring nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Physical Education & Sports Medicine (AREA)
- Emergency Medicine (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Compression, Expansion, Code Conversion, And Decoders (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP10382330A EP2460519A1 (en) | 2010-12-03 | 2010-12-03 | Use of sigma ligands in bone cancer pain |
| PCT/EP2011/071584 WO2012072782A1 (en) | 2010-12-03 | 2011-12-02 | Use of sigma ligands in bone cancer pain |
| EP11794082.5A EP2646025B1 (en) | 2010-12-03 | 2011-12-02 | Use of sigma ligands in bone cancer pain |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ME02852B true ME02852B (me) | 2018-04-20 |
Family
ID=43629676
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MEP-2017-120A ME02852B (me) | 2010-12-03 | 2011-12-02 | Upotreba sigma liganada kod bola usled raka kostiju |
Country Status (35)
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2116539A1 (en) | 2008-04-25 | 2009-11-11 | Laboratorios Del. Dr. Esteve, S.A. | 1-aryl-3-aminoalkoxy-pyrazoles as sigma ligands enhancing analgesic effects of opioids and attenuating the dependency thereof |
| EP2353598A1 (en) | 2010-02-04 | 2011-08-10 | Laboratorios Del. Dr. Esteve, S.A. | Sigma ligands for use in the prevention and/or treatment of postoperative pain |
| EP2353591A1 (en) | 2010-02-04 | 2011-08-10 | Laboratorios Del. Dr. Esteve, S.A. | Sigma ligands for potentiating the analgesic effect of opioids and opiates in post-operative pain and attenuating the dependency thereof |
| EP2388005A1 (en) | 2010-05-21 | 2011-11-23 | Laboratorios Del. Dr. Esteve, S.A. | Sigma ligands for the prevention and/or treatment of emesis induced by chemotherapy or radiotherapy |
| EP2415471A1 (en) | 2010-08-03 | 2012-02-08 | Laboratorios Del. Dr. Esteve, S.A. | Use of sigma ligands in opioid-induced hyperalgesia |
| EP2426111A1 (en) * | 2010-08-09 | 2012-03-07 | Laboratorios Del. Dr. Esteve, S.A. | 4-[-2-[[5-methyl-1-(2-naphtalenyl)-1h-pyrazol-3-yl]oxy]ethyl]morpholine hydrochloride amorphous solid forms |
| EP2524694A1 (en) | 2011-05-19 | 2012-11-21 | Laboratorios Del. Dr. Esteve, S.A. | Use of sigma ligands in diabetes type-2 associated pain |
| EP2792352A1 (en) | 2013-04-16 | 2014-10-22 | Laboratorios Del. Dr. Esteve, S.A. | Alpha-2 adrenoreceptor and sigma receptor ligand combinations |
| EP2818166A1 (en) * | 2013-06-26 | 2014-12-31 | Laboratorios del Dr. Esteve S.A. | Use of sigma receptor ligands for the prevention and treatment of pain associated to interstitial cystitis/bladder pain syndrome (IC/BPS) |
| MX2016002892A (es) * | 2013-09-12 | 2016-06-10 | Esteve Labor Dr | Combinaciones de ligando de receptores sigma y aine. |
| SG11201604480PA (en) | 2013-12-17 | 2016-07-28 | Esteve Labor Dr | SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITORS (SNRIs) AND SIGMA RECEPTOR LIGANDS COMBINATIONS |
| MX2016007286A (es) | 2013-12-17 | 2016-08-04 | Esteve Labor Dr | Combinaciones de gabapentinoides y ligandos de receptores sigma. |
| EP2929883A1 (en) * | 2014-04-08 | 2015-10-14 | Institut Pasteur | Pyrazole derivatives as dihydroorotate dehydrogenase (DHODH) inhibitors |
| WO2018011169A1 (en) * | 2016-07-12 | 2018-01-18 | Laboratorios Del Dr. Esteve, S.A. | Use of sigma receptor ligands in post-herpetic pain |
| EP3415143A1 (en) * | 2017-06-16 | 2018-12-19 | Kai-Uwe Kern | Bromhexine for the treatment of pain |
| WO2019224184A1 (en) * | 2018-05-21 | 2019-11-28 | Ipsen Biopharm Limited | Suppression of bone cancer-induced allodynia |
| AU2019387370A1 (en) | 2018-11-30 | 2021-06-10 | Nuvation Bio Inc. | Pyrrole and pyrazole compounds and methods of use thereof |
| CN112341397B (zh) * | 2019-08-09 | 2023-05-23 | 成都苑东生物制药股份有限公司 | 吡嗪类衍生物或盐、异构体、其制备方法及用途 |
| KR102744822B1 (ko) | 2020-06-05 | 2024-12-20 | 주식회사 허밍아비스 | 발열체 조성물 및 이를 이용한 마스크 제조방법 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1832928B (zh) * | 2003-06-26 | 2012-07-04 | 诺瓦提斯公司 | 以5元杂环为基础的p38激酶抑制剂 |
| MX2007002341A (es) * | 2004-08-27 | 2007-09-25 | Esteve Labor Dr | Inhibidores del receptor sigma. |
| KR101352012B1 (ko) * | 2004-08-27 | 2014-01-15 | 라보라토리오스 델 드라. 에스테브.에스.에이. | 시그마 수용체 저해제 |
| WO2007098953A1 (en) * | 2006-03-01 | 2007-09-07 | Laboratorios Del Dr. Esteve, S.A. | Pyrazole derivatives as sigma receptor inhibitors |
| EP2116539A1 (en) * | 2008-04-25 | 2009-11-11 | Laboratorios Del. Dr. Esteve, S.A. | 1-aryl-3-aminoalkoxy-pyrazoles as sigma ligands enhancing analgesic effects of opioids and attenuating the dependency thereof |
| EP2113501A1 (en) * | 2008-04-25 | 2009-11-04 | Laboratorios Del. Dr. Esteve, S.A. | 5-Methyl-1-(naphthalen-2-YL)-1H-Pyrazoles useful as sigma receptor inhibitors |
| EP2353591A1 (en) * | 2010-02-04 | 2011-08-10 | Laboratorios Del. Dr. Esteve, S.A. | Sigma ligands for potentiating the analgesic effect of opioids and opiates in post-operative pain and attenuating the dependency thereof |
-
2010
- 2010-12-03 EP EP10382330A patent/EP2460519A1/en not_active Withdrawn
-
2011
- 2011-02-12 UA UAA201308348A patent/UA112638C2/uk unknown
- 2011-11-25 TW TW100143323A patent/TWI629060B/zh not_active IP Right Cessation
- 2011-12-02 NZ NZ612119A patent/NZ612119A/en not_active IP Right Cessation
- 2011-12-02 RU RU2013130222/15A patent/RU2585095C2/ru not_active IP Right Cessation
- 2011-12-02 JP JP2013541369A patent/JP6027014B2/ja not_active Expired - Fee Related
- 2011-12-02 KR KR1020137017344A patent/KR101855358B1/ko not_active Expired - Fee Related
- 2011-12-02 SG SG2013042569A patent/SG190745A1/en unknown
- 2011-12-02 SM SM20170270T patent/SMT201700270T1/it unknown
- 2011-12-02 BR BR112013013369A patent/BR112013013369A8/pt not_active Application Discontinuation
- 2011-12-02 HR HRP20170818TT patent/HRP20170818T1/hr unknown
- 2011-12-02 TR TR2017/08567T patent/TR201708567T4/tr unknown
- 2011-12-02 MX MX2013006140A patent/MX343773B/es active IP Right Grant
- 2011-12-02 PL PL11794082T patent/PL2646025T3/pl unknown
- 2011-12-02 MY MYPI2013001961A patent/MY171994A/en unknown
- 2011-12-02 PH PH1/2013/501127A patent/PH12013501127A1/en unknown
- 2011-12-02 CA CA2819442A patent/CA2819442C/en not_active Expired - Fee Related
- 2011-12-02 US US13/991,282 patent/US20130324535A1/en not_active Abandoned
- 2011-12-02 SI SI201131191A patent/SI2646025T1/sl unknown
- 2011-12-02 AR ARP110104502A patent/AR084730A1/es unknown
- 2011-12-02 ME MEP-2017-120A patent/ME02852B/me unknown
- 2011-12-02 EP EP11794082.5A patent/EP2646025B1/en active Active
- 2011-12-02 HU HUE11794082A patent/HUE033488T2/en unknown
- 2011-12-02 DK DK11794082.5T patent/DK2646025T3/en active
- 2011-12-02 WO PCT/EP2011/071584 patent/WO2012072782A1/en not_active Ceased
- 2011-12-02 CN CN201180065232.XA patent/CN103313709B/zh not_active Expired - Fee Related
- 2011-12-02 RS RS20170575A patent/RS56081B1/sr unknown
- 2011-12-02 LT LTEP11794082.5T patent/LT2646025T/lt unknown
- 2011-12-02 MA MA36072A patent/MA34878B1/fr unknown
- 2011-12-02 ES ES11794082.5T patent/ES2626672T3/es active Active
- 2011-12-02 PT PT117940825T patent/PT2646025T/pt unknown
-
2013
- 2013-05-29 TN TNP2013000227A patent/TN2013000227A1/fr unknown
- 2013-06-03 IL IL226706A patent/IL226706A/en active IP Right Grant
- 2013-07-02 CO CO13155721A patent/CO6781549A2/es not_active Application Discontinuation
- 2013-07-03 ZA ZA2013/04966A patent/ZA201304966B/en unknown
-
2017
- 2017-06-08 CY CY20171100604T patent/CY1119030T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20170818T1 (hr) | Upotreba sigma liganada protiv boli kod raka kostiju | |
| EP4663636A3 (en) | Trifluoromethyl substituted pyrazoles as human plasma kallikrein inhibitors | |
| FI3256218T3 (fi) | Kdm1a-estäjät sairauksien hoidossa | |
| EP4406950A3 (en) | Lfa-1 inhibitor and polymorph thereof | |
| HK1211475A1 (en) | Combination therapy | |
| TN2013000253A1 (en) | Bicyclo[3.2.1]octyl amide derivatives and uses of same | |
| IN2014KN00948A (enExample) | ||
| UA117983C2 (uk) | Інгібітор кінази aurora a | |
| MX381994B (es) | Inhibidor de janus quinasa. | |
| CL2014000299A1 (es) | Compuestos derivados de n-[1-ciano-2-(fenil)etil]-2-azabiciclo[2.2.1]heptan-3-carboxamidas sustituidas, inhibidores de catepsina c; composicion farmaceutica; metodo de tratamiento o prevencion; y uso para el tratamiento de enfermedades tales como asma, enfermedades alergicas, artritis reumatoidea y aterosclerosis, entre otras. | |
| NZ712207A (en) | Tetrahydropyrrolothiazine compounds | |
| WO2012156317A3 (en) | Intranasal pharmaceutical dosage forms comprising naloxone | |
| WO2012118308A3 (ko) | 피라졸 유도체를 포함하는 심혈관 질환 예방 및 치료용 조성물. | |
| IN2014DN06869A (enExample) | ||
| MX2021010297A (es) | Inhibidores de calicreina plasmatica humana. | |
| MX2017012295A (es) | Derivados formilados n-heterociclicos como inhibidores de fgfr4. | |
| PH12016502353A1 (en) | Pharmaceutical composition | |
| PH12018500377A1 (en) | Novel annelated benzamides | |
| PH12016502246B1 (en) | Carboxamide derivatives | |
| IN2014CN00981A (enExample) | ||
| BR112013018781A2 (pt) | composto derivado de piridona, e, composição farmacêutica | |
| PH12013501830A1 (en) | Peptide deformylase inhibitors | |
| WO2013033602A3 (en) | Fatty acid amides, compositions and methods of use | |
| IL240136A0 (en) | Pharmaceutical preparations containing n-[3-chloro-4-(3-fluorobenzyloxy)phenyl]-6-[5({[2-(methylsulfonyl)ethyl]amino}methyl)-2-furyl]quinazolin-4-amine or salt Pharmacists accept, solvate or its dissolved salt | |
| EP2636677A4 (en) | CDK-HEMMENDES PYRROLOPYRIMIDINONCARBOXAMID DERIVATIVE OR PHARMACEUTICAL ACCEPTABLE SALT AND THE PHARMACEUTICAL COMPOSITION CONTAINING THEREOF FOR THE PREVENTION OR TREATMENT OF LIVER CELL CARCINOMA |